株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品ホールセール & 流通業者トップ20:ブランド医薬品・ジェネリック医薬品・主要企業 (2019年)

Top 30 Pharmaceutical Wholesale & Distribution Organizations 2019: Branded Drugs, Generic Drugs, Leading Companies

発行 Visiongain Ltd 商品コード 752340
出版日 ページ情報 英文 253 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
医薬品ホールセール & 流通業者トップ20:ブランド医薬品・ジェネリック医薬品・主要企業 (2019年) Top 30 Pharmaceutical Wholesale & Distribution Organizations 2019: Branded Drugs, Generic Drugs, Leading Companies
出版日: 2019年06月28日 ページ情報: 英文 253 Pages
概要

当レポートでは、世界の医薬品ホールセール・流通市場について調査し、世界における市場規模の実績と予測、2次市場別の実績と予測、SWOT分析・STEP分析、および主要企業20社のプロファイルを提供しています。

第1章 レポート概要

第2章 イントロダクション:医薬品ホールセール・流通

  • 医薬品ホールセラーの役割:医薬品産業のブローカー
  • 流通チェーン:ホールセラー vs. 物流サービスプロバイダー
  • 収益・利益の生成

第3章 世界の医薬品ホールセール・流通市場

  • 世界の医薬品ホールセール・流通市場:政府による値下げの制限・ジェネリック医薬品の代替
  • 医薬品ホールセール・流通産業:世界市場の予測
  • ブランド医薬品・ジェネリック医薬品:生成収益

第4章 主な医薬品ホールセール・流通業者:現在・将来のパフォーマンス

  • McKesson: 米国における最古かつ最大のヘルスケアサービス企業
  • Cardinal Health: 世界第3位の医薬品ホールセラー
  • AmerisourceBergen: 世界第3位の医薬品ホールセール・流通業者
  • Walgreens Boots Alliance: 米国における最大のドラッグストアチェーンおよび世界的なホールセール・流通ネットワーク
  • メディパルホールディングス:日本トップの医薬品ホールセラー
  • Phoenix Group: 欧州最大のホールセラー
  • SINOPHARM: 中国トップの医薬品ホールセール・流通業者
  • アルフレッサ ホールディングス: 日本で第2位の医薬品ホールセール・流通業者
  • スズケン:日本で最初の全国的ホールセラー
  • Shanghai Pharmaceuticals Holding:中国第2位のホールセラー
  • Morris & Dickson Co. LLC: 175年以上の貢献
  • H.D. Smith:米国最大の独立型ホールセラー
  • Smith Drug Company:米国で1400以上の顧客を抱える
  • CuraScript Specialty Distribution
  • Mawdsley-Brooks & Co. Ltd.
  • North Carolina Mutual Wholesale Drug: 65年の貢献
  • Prodigy Health
  • Fortissa Limited: 20年の幅広い経験
  • CR Pharmaceutical

第5章 医薬品ホールセール・流通市場の定性分析

  • 強み・弱み
  • 機会・脅威
  • 社会、技術、経済、および政治的影響要因 (STEP分析)

第6章 結論

図表

List of Tables

  • TABLE 2.1 USE OF DTP MODEL IN THE UK, 2007-2012
  • TABLE 3.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), AGR (%), CAGR (%), 2019-2029
  • TABLE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION BY SEGMENT: REVENUE ($BN) FORECASTS, AGR (%), CAGR (%) AND MARKET SHARES (%), 2019-2029
  • TABLE 3.3 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECASTS, AGR (%), CAGR (%), 2019-2029
  • TABLE 3.4 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECASTS, AGR (%), CAGR (%), 2019-2029
  • TABLE 4.1 MCKESSON, DISTRIBUTION SOLUTIONS: SERVICES AND CUSTOMERS, 2018
  • TABLE 4.2 MCKESSON, TECHNOLOGY SOLUTIONS: SERVICES AND CUSTOMERS, 2018
  • TABLE 4.3 MCKESSON, TECHNOLOGY SOLUTIONS: MANAGEMENT MEMBERS, 2018
  • TABLE 4.4 MCKESSON: HISTORICAL REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT ($BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2008-2018
  • TABLE 4.5 MCKESSON REVENUE ($BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.6 MCKESSON: GROSS PROFIT ($BN), GROSS PROFIT SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.7 ACQUISITIONS BY MCKESSON, 2007-2018
  • TABLE 4.8 MCKESSON: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.9 MCKESSON: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.10 MCKESSON: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
  • TABLE 4.11 CARDINAL HEALTH: MANAGEMENT MEMBERS, 2018
  • TABLE 4.12 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), OPERATING EARNINGS ($BN), AGR (%) AND CAGR (%), 2008-2018
  • TABLE 4.13 CARDINAL HEALTH: REVENUE ($BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.14 CARDINAL HEALTH: OPERATING EARNINGS ($BN) AND ANNUAL GROWTH (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.15 CARDINAL HEALTH: REVENUE ($BN) AND REVENUE SHARE (%) BREAKDOWN BY CUSTOMER, 2018
  • TABLE 4.16 SELECTED ACQUISITIONS BY CARDINAL HEALTH AND THEIR LINE OF BUSINESS, 2008-2018
  • TABLE 4.17 CARDINAL HEALTH: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.18 CARDINAL HEALTH: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.19 CARDINAL HEALTH: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
  • TABLE 4.20 AMERISOURCEBERGEN: MANAGEMENT MEMBERS, 2018
  • TABLE 4.21 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), OPERATING INCOME ($BN), OPERATING INCOME AGR (%) AND OPERATING INCOME CAGR (%), 2008-2018
  • TABLE 4.22 AMERISOURCEBERGEN: REVENUE ($BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.23 AMERISOURCEBERGEN: GROSS PROFIT ($BN), GROSS PROFIT SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.24 AMERISOURCEBERGEN: REVENUE ($BN) AND REVENUE SHARE (%) BREAKDOWN BY CUSTOMER, 2018
  • TABLE 4.25 ACQUISITIONS BY AMERISOURCEBERGEN AND THEIR LINE OF BUSINESS, 2008-2018
  • TABLE 4.26 AMERISOURCEBERGEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.27 AMERISOURCEBERGEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.28 AMERISOURCEBERGEN: STRATEGIC MOVES & DEVELOPMENTS, 2017-2019
  • TABLE 4.29 WALGREENS BOOTS ALLIANCE: MANAGEMENT MEMBERS, 2018
  • TABLE 4.30 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT ($BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
  • TABLE 4.31 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.32 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.33 WALGREENS BOOTS ALLIANCE: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
  • TABLE 4.34 MEDIPAL HOLDINGS: CONSOLIDATED SUBSIDIARY COMPANIES, 2016
  • TABLE 4.35 MEDIPAL HOLDINGS: MANAGEMENT MEMBERS, 2018
  • TABLE 4.36 MEDIPAL HOLDINGS: HISTORICAL REVENUE (¥BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT AGR (%), 2008-2018
  • TABLE 4.37 MEDIPAL HOLDINGS: REVENUE (¥BN) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2019
  • TABLE 4.38 MEDIPAL HOLDINGS: OPERATING PROFIT (¥BN), AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
  • TABLE 4.39 MEDIPAL HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.40 MEDIPAL HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.41 PHOENIX GROUP: MANAGEMENT MEMBERS, 2018
  • TABLE 4.42 PHOENIX GROUP: SUBSIDIARY COMPANIES, 2018
  • TABLE 4.43 PHOENIX GROUP: HISTORICAL REVENUE (€BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (€BN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
  • TABLE 4.44 PHOENIX GROUP: REVENUE SHARE (%) BREAKDOWN BY REGION, 2017-2018
  • TABLE 4.45 PHOENIX GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.46 PHOENIX GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.47 SINOPHARM: MANAGEMENT MEMBERS, 2018
  • TABLE 4.48 SINOPHARM GROUP: HISTORICAL REVENUE (RMBBN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (RMBBN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
  • TABLE 4.49 SINOPHARM GROUP: REVENUE (RMBBN, $BN) AND REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
  • TABLE 4.50 SINOPHARM GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.51 SINOPHARM GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.52 ALFRESA HOLDINGS: LIST OF SIGNIFICANT SUBSIDIARIES AND AFFILIATES, 2018
  • TABLE 4.53 ALFRESA HOLDINGS: MANAGEMENT MEMBERS, 2018
  • TABLE 4.54 ALFRESA HOLDINGS: HISTORICAL REVENUE (¥BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (¥BN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
  • TABLE 4.55 ALFRESA HOLDINGS: BUSINESS STRATEGIES, 2013-2018
  • TABLE 4.56 ALFRESA HOLDINGS: REVENUE (¥BN, $BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
  • TABLE 4.57 ALFRESA HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.58 ALFRESA HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.59 SUZUKEN CO., LTD: MANAGEMENT MEMBERS, 2018
  • TABLE 4.60 SUZUKEN: HISTORICAL REVENUE (¥BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (¥BN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
  • TABLE 4.61 SUZUKEN: REVENUE (¥BN, $BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
  • TABLE 4.62 SUZUKEN: OPERATING INCOME (¥BN, $BN), OPERATING INCOME SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
  • TABLE 4.63 SUZUKEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.64 SUZUKEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.65 SUZUKEN: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
  • TABLE 4.66 SHANGHAI PHARMACEUTICALS HOLDING: MANAGEMENT MEMBERS, 2018
  • TABLE 4.67 SHANGHAI PHARMACEUTICALS HOLDING: HISTORICAL REVENUE (RMBBN, $BN), REVENUE AGR (%), REVENUE CAGR (%), 2011-2018
  • TABLE 4.68 SHANGHAI PHARMACEUTICALS HOLDING: REVENUE (RMBBN, $BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
  • TABLE 4.69 SHANGHAI PHARMACEUTICALS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
  • TABLE 4.70 SHANGHAI PHARMACEUTICALS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
  • TABLE 4.71 MORRIS & DICKSON CO. LLC PROFILE 2018
  • TABLE 4.72 SMITH DRUG COMPANY, PROFILE 2018
  • TABLE 4.73 ANDA, INC. PROFILE 2018
  • TABLE 4.74 CURASCRIPT SPECIALTY DISTRIBUTION. PROFILE 2018
  • TABLE 4.75 MAWDSLEY-BROOKS & CO. LTD. PROFILE 2018
  • TABLE 4.76 NORTH CAROLINA MUTUAL WHOLESALE DRUG PROFILE 2018
  • TABLE 4.77 PRODIGY HEALTH PROFILE 2018
  • TABLE 4.78 FORTISSA LIMITED PROFILE 2018
  • TABLE 4.79 CR PHARMACEUTICAL PROFILE 2018
  • TABLE 4.80 HYGEN PHARMACEUTICALS INC.: PROFILE 2018
  • TABLE 4.81 FFF ENTERPRISES INC. PROFILE 2018
  • TABLE 4.82 ROCHESTER DRUG COOPERATIVE, PROFILE 2018
  • TABLE 4.83 AUBURN PHARMACEUTICAL COMPANY, PROFILE 2018
  • TABLE 4.84 AUBURN PHARMACEUTICAL COMPANY, GENERIC PRODUCT WITH LAUNCH DATES
  • TABLE 4.85 CAPITAL WHOLESALE DRUG COMPANY, PROFILE 2018
  • TABLE 4.86 REALCAN PHARMACEUTICAL GROUP CO., LTD., PROFILE 2018
  • TABLE 4.87 PROFARMA DISTRIBUIDORA DE PRODUTOS FARMACEUTICOS SA, PROFILE 2018
  • TABLE 4.88 DAKOTA DRUG, INC., PROFILE 2018
  • TABLE 4.89 ZHEJIANG INTL GROUP CO., LTD., PROFILE 2018
  • TABLE 4.90 OHKI HEALTH CARE HOLDINGS, INC., PROFILE 2018
  • TABLE 4.91 KINGWORLD MEDICINES GROUP LTD., PROFILE 2018
  • TABLE 5.1 THE PHARMACEUTICAL W&D MARKET: STRENGTHS AND WEAKNESSES
  • TABLE 5.2 THE PHARMACEUTICAL W&D MARKET: OPPORTUNITIES AND THREATS
  • TABLE 5.3 STRENGTHS AND WEAKNESSES OF THE DTP DISTRIBUTION MODEL
  • TABLE 5.4 ITR RATINGS AND CORRESPONDING REIMBURSEMENT RATES, 2018
  • TABLE 5.5 SOCIAL, TECHNOLOGICAL, ECONOMIC AND POLITICAL FACTORS INFLUENCING THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET (STEP ANALYSIS)

List of Figures

  • FIGURE 2.1 ROUTES OF DRUG DISTRIBUTION, 2018
  • FIGURE 3.1 THE GLOBAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), 2018-2029
  • FIGURE 3.3 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: MARKET SHARES (%), 2018
  • FIGURE 3.4 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: MARKET SHARES (%), 2024
  • FIGURE 3.5 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: MARKET SHARES (%), 2029
  • FIGURE 3.6 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: REVENUE FORECASTS ($BN), 2018-2029
  • FIGURE 3.7 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 3.8 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECAST, 2018-2029
  • FIGURE 4.1 MCKESSON: HISTORICAL REVENUE ($BN), REVENUE AGR (%), GROSS PROFIT ($BN) AND GROSS PROFIT AGR (%), 2008-2018
  • FIGURE 4.2 MCKESSON: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.3 MCKESSON: GROSS PROFIT SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.4 MCKESSON: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.5 MCKESSON: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.6 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), REVENUE AGR (%), OPERATING EARNINGS ($BN) AND OPERATING EARNINGS AGR(%), 2008-2018
  • FIGURE 4.7 CARDINAL HEALTH: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.8 CARDINAL HEALTH: REVENUE SHARE (%) BREAKDOWN BY CUSTOMER, 2018
  • FIGURE 4.9 CARDINAL HEALTH: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.10 CARDINAL HEALTH: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.11 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), REVENUE AGR (%), OPERATING INCOME ($BN) AND OPERATING INCOME AGR (%), 2008-2018
  • FIGURE 4.12 AMERISOURCEBERGEN: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.13 AMERISOURCEBERGEN: REVENUE ($BN) BREAKDOWN BY CUSTOMER, 2018
  • FIGURE 4.14 AMERISOURCEBERGEN: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.15 AMERISOURCEBERGEN: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.16 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), REVENUE AGR (%), GROSS PROFIT ($BN) AND GROSS PROFIT AGR (%), 2011-2018
  • FIGURE 4.17 WALGREENS BOOTS ALLIANCE: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.18 WALGREENS BOOTS ALLIANCE: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.19 WALGREENS BOOTS ALLIANCE: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.20 MEDIPAL HOLDINGS: HISTORICAL REVENUE (¥BN), REVENUE AGR (%), AND GROSS PROFIT AGR (%), 2008-2018
  • FIGURE 4.21 MEDIPAL HOLDINGS: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.22 MEDIPAL HOLDINGS: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.23 MEDIPAL HOLDINGS: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.24 PHOENIX GROUP: HISTORICAL REVENUE (£BN), REVENUE AGR (%), GROSS PROFIT (£BN) AND GROSS PROFIT AGR (%), 2011-2018
  • FIGURE 4.25 PHOENIX GROUP: REVENUE SHARE (%) BREAKDOWN BY REGION, 2018
  • FIGURE 4.26 PHOENIX GROUP: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.27 PHOENIX GROUP DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.28 SINOPHARM GROUP: HISTORICAL REVENUE (RMBBN), REVENUE AGR (%), GROSS PROFIT (RMBBN) AND GROSS PROFIT AGR (%), 2011-2018
  • FIGURE 4.29 SINOPHARM GROUP: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.30 SINOPHARM GROUP: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.31 ALFRESA HOLDINGS: HISTORICAL REVENUE (¥BN), REVENUE AGR (%), GROSS PROFIT (¥BN), GROSS PROFIT AGR (%), 2011-2018
  • FIGURE 4.32 ALFRESA HOLDINGS: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.33 ALFRESA HOLDINGS: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.34 ALFRESA HOLDINGS: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.35 SUZUKEN: HISTORICAL REVENUE (¥BN), REVENUE AGR (%), GROSS PROFIT (¥BN) AND GROSS PROFIT AGR (%), 2011-2018
  • FIGURE 4.36 SUZUKEN: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.37 SUZUKEN: OPERATING INCOME SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.38 SUZUKEN: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.39 SUZUKEN: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 4.40 SHANGHAI PHARMACEUTICALS HOLDING: HISTORICAL REVENUE (RMBBN), REVENUE AGR (%), 2011-2018
  • FIGURE 4.41 SHANGHAI PHARMACEUTICALS HOLDING: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
  • FIGURE 4.42 SHANGHAI PHARMACEUTICALS HOLDING: REVENUE ($BN) FORECAST, 2019-2029
  • FIGURE 4.43 SHANGHAI PHARMACEUTICALS HOLDING: DRIVERS AND RESTRAINTS, 2018
  • FIGURE 5.1 COMPARISON OF THE WHOLESALE AND DTP ROUTES OF DISTRIBUTION, 2018
  • FIGURE 6.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: GLOBAL MARKET FORECASTS ($BN) BY SUBMARKET, 2019-2029
  • FIGURE 6.2 LEADING NATIONAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKETS: REVENUE PROJECTIONS ($BN), 2018, 2024 AND 2029
  • FIGURE 6.3 LEADING PHARMACEUTICAL WHOLESALE AND DISTRIBUTION COMPANIES: REVENUE ($BN) PROJECTIONS 2018, 2024 AND 2029

Companies Listed

  • AAH Pharmaceuticals
  • AccessClosure
  • Acofarma (Asociaci£n Cooperativas Farmacéuticas)
  • ADG Apotheken-Dienstleistungsgesellschaft mbH
  • Admenta
  • Alfresa Fine Chemical Corporation
  • Alfresa Holdings
  • Alliance Boots
  • Alliance Healthcare
  • Alliance Santé
  • Alliance UniChem
  • AmeriSource Health
  • AmerisourceBergen
  • AmerisourceBergen Canada
  • AmerisourceBergen Drug Corporation (ABDC)
  • AmerisourceBergen Specialty Group (ABSG)
  • Anda Inc.
  • Apollo Medical Holdings
  • ASTEC Co., Ltd.
  • ASTIS Co., Ltd.
  • Athos Farma
  • ATOL CO., LTD.
  • Auburn Pharmaceutical Company
  • Azwell
  • Bayer
  • BENU Apotheek
  • Bergen Brunswig
  • Biologics Inc
  • Boots Group
  • Bristol-Myers Squibb
  • Brocacef Groep NV
  • Brocacef Holding
  • Bundesverband des Pharmazeutischen Grosshandel
  • Capital Wholesale Drug Company
  • Cardinal Health
  • Caremark Rx
  • Celesio AG
  • CERP Bretagne Nord
  • CERP Rhin Rhone Mediterranee
  • CERP Rouen
  • Chiyaku Co
  • Chuounyu Co., Ltd.
  • Cloumed Corporation
  • Cofares
  • Comifar
  • Cordis
  • CoverMyMeds
  • CoverMyMeds LLC
  • CR Pharmaceutical
  • CuraScript Special
  • CVS Caremark
  • CVS Corporation
  • CVS Health Corporation
  • Cystic Fibrosis Foundation Pharmacy, LLC
  • Daiichi Sankyo Propharma Co.
  • Dakota Drug, Inc.
  • Dong Ying (Jiangsu) Pharmaceuticals Co., Ltd.
  • Drogarias Tamoio
  • Drug Trading Company Ltd
  • Dutch ACM
  • Emart Company
  • ENSHU YAKUHIN CO., LTD.
  • Ethicon
  • EVERLTH AGROTECH Co., Ltd.
  • EVERLTH Co., Ltd.
  • Farcopa Distribuzione
  • Fff Enterprises Inc.
  • Fortissa Limited
  • Fukujin Co.
  • Good Service Co
  • Guangzhou Pharmaceutical Company Ltd.
  • Guangzhou Pharmaceuticals Corporation
  • Harvard Drug
  • Hedef Alliance
  • Hefame
  • HEISEI YAKUHIN CO., LTD.
  • HyGen Pharmaceuticals Inc.
  • IZUTSU KURAYA SANSEIDO Inc.
  • IZUTSU PHARMACEUTICAL CO. LTD.
  • Japanese Pharmaceutical Wholesalers Association
  • Jingu Yakuhin Co., Ltd.
  • Johnson & Johnson
  • Katren
  • Kenzmedico Co., Ltd.
  • Kerr Drug
  • Kingworld Medicines Group Ltd.
  • KOBASHOU. CO., LTD.
  • KURAYA SANSEIDO Inc
  • Life Medicom Co., Ltd.
  • Lloyds Pharmacy
  • MARUZEN YAKUHIN CO., LTD.
  • Mawdsley-Brooks & Co. Ltd.
  • McKesson
  • McQueary Brothers of Springfield
  • Medical Specialties Distributors
  • MEDICEO CORPORATION
  • Medicine Shoppe Canada Inc.
  • MEDIE Co., Ltd.
  • MEDIPAL HOLDINGS CORPORATION
  • Mediq Apotheken Nederland B.V.
  • Medtronic
  • Meinan Distribution Center
  • Metro Medical Supply Inc
  • Mitsubishi
  • MM CORPORATION
  • Morris & Dickson Co. LLC
  • MP AGRO CO., LTD.
  • MVC CO., LTD
  • MWI Veterinary Supply, Inc.
  • Nadro
  • Nakano Yakuhin Co., Ltd.
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority (NPPA)
  • Nihon Apoch Co.
  • North Carolina Mutual Wholesale Drug
  • Novo Nordisk
  • Novodata Zrt.
  • Numark
  • OCP
  • Ohki Health Care Holdings, Inc.
  • Oncology Therapeutics
  • Oncoprod
  • OptumRx
  • P.J.D. Network
  • PALTAC CORPORATION
  • Paltac Corporation
  • Panpharma
  • Pfercos Co., Ltd.
  • Pfizer
  • PharMEDium
  • Polska Grupa Farmaceutyczna
  • Prodigy Health
  • Profarma Distribuidora de Produtos Farmaceuticos SA
  • Prosper
  • Protek
  • PSC Co, Ltd.
  • PSS World Medical Inc.
  • Ratiopharm
  • RDC Kanto5
  • Realcan Pharmaceutical Group Co., Ltd
  • Red Oak Sourcing
  • Red Oak, LLC
  • Rexall Health
  • Rite Aid Corporation
  • Rochester Drug Cooperative
  • Rosta
  • RxCrossroads
  • S. D.Collabo Co.,Ltd.
  • S.D.Logi CO., Ltd.
  • Sakurai Tsusho Corporation
  • Sanacorp
  • Sandoz
  • Sanki Corporation
  • Sanki MediHeart Limited
  • Sanki Wellbe Co., Ltd.
  • Sannova
  • Sanwa Kagaku Kenkyusho Co., Ltd.
  • S-Care Mate Co., Ltd.
  • Sciclone Trade
  • SEIWA SANGYO CO
  • Shanghai Fosun Pharmaceutical
  • Shanghai Pharma Zhenjiang Co., Ltd.
  • Shanghai Pharmaceutical Holdings
  • Shinohara Chemicals
  • Shinsegai Group
  • Shoyaku Co., Ltd.
  • SIA International
  • Sincamesp
  • SINOPHARM
  • S-mile, Inc
  • Smith Drug Company
  • Sonexus Health
  • SPH Jiangxi Shangrao Pharmaceutical Co., Ltd.
  • SPH Keyuan Xinhai Pharmaceutical Hebei Co., Ltd.
  • SPH Keyuan Xinhai Pharmaceutical Heilongjiang Co., Ltd.
  • SPLine Corporation
  • Suzuken Co., Ltd.
  • Suzuken Iwate Co., Ltd.
  • Suzuken Medical Instruments Co, Ltd
  • Suzuken Okinawa Yakuhin Co., Ltd.
  • The PHOENIX Group
  • Toho Holdings
  • Tokiwa Yakuhin Co
  • Torfarm
  • Tradex International
  • TS Alfresa Corporation
  • UniChem
  • US Oncology Holdings, Inc.
  • USHIODA KURAYA SANSEIDO Inc.
  • USHIODA SANGOKUDO YAKUHIN CO., LTD.
  • Vaccine Safe Co
  • Vantage Oncology
  • Victoria Merger Sub, Inc.
  • Vitaco Holdings
  • Walgreen
  • Walgreens Boots Alliance
  • World Courier Group Inc.
  • Wyeth Pharmaceuticals
  • YAMAHIRO KURAYA SANSEIDO Inc.
  • Yunnan Pharmaceutical Co., Ltd.
  • Zhejiang Intl Group Co., Ltd.
  • Zuellig Pharma
目次
Product Code: PHA0454

The pharmaceutical wholesale and distribution market is vital, providing access to life saving drugs to vast number of people in a timely manner. The market is large, with many opportunities for growth and development during the forecast period.

The establishment of the pharmaceutical wholesale market was driven by manufacturers wanting to outsource distribution to wholesalers to focus on core competencies of R&D and marketing. At the same time, hospitals outsourced inventory management in an effort to reduce investment in this area. These factors created a high demand for a comprehensive wholesale and distribution service.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 253-page report you will receive 157 charts - all unavailable elsewhere.

The 253-page report provides clear detailed insight into the leading pharmaceutical wholesale & distribution organizations. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Pharmaceutical Wholesale & Distribution Market Size Forecast from 2019-2029
  • Global Pharmaceutical Wholesale & Distribution Market Size Forecast from 2019-2029 segmented by submarket:
  • Branded Drugs
  • Generic Drugs
  • Others
  • A SWOT and STEP analysis of the global pharmaceutical wholesale & distribution market
  • Profiles of the 30 leading pharmaceutical wholesale & distribution organizations:
  • Alfresa Holdings
  • AmerisourceBergen
  • Anda Inc.
  • Auburn Pharmaceutical Company
  • Capital Wholesale Drug Company
  • Cardinal Health
  • CR Pharmaceutical
  • CuraScript Special
  • Dakota Drug, Inc.
  • Fff Enterprises Inc.
  • Fortissa Limited
  • HyGen Pharmaceuticals Inc.
  • Kingworld Medicines Group Ltd.
  • Mawdsley-Brooks & Co. Ltd.
  • McKesson
  • MEDIPAL HOLDINGS
  • Morris & Dickson Co. LLC
  • North Carolina Mutual Wholesale Drug
  • Ohki Health Care Holdings, Inc.
  • Prodigy Health
  • Profarma Distribuidora de Produtos Farmaceuticos SA
  • Realcan Pharmaceutical Group Co., Ltd
  • Rochester Drug Cooperative
  • Shanghai Pharmaceutical Holdings.
  • SINOPHARM
  • Smith Drug Company
  • SUZUKEN
  • The PHOENIX Group
  • Walgreens Boots Alliance
  • Zhejiang Intl Group Co., Ltd.

image1

  • The content of each profile differs, depending on the organization. In general, a profile gives the following information:
  • Overview of the company's services and operations
  • Analysis of recent financial performance - annual revenue for services, including data on operating profit and margins
  • Revenue forecast from 2019 to 2029
  • Assessment of developments - activities, acquisitions, production capacity, deals, new service offerings and collaborations
  • Sales Force Structure
  • Key Questions Answered by this Report:
  • How is the pharmaceutical wholesale and distribution drug market evolving?
  • What is driving and restraining the pharmaceutical wholesale and distribution industry?
  • What are the market shares of main segments of the world pharmaceutical wholesale and distribution market?
  • How will each submarket grow over the forecast period and how much revenue will these segments account for in 2029?
  • How will the market shares for pharmaceutical wholesale and distribution submarkets develop from 2018 to 2029?
  • What will be the main sales drivers for the overall market and components from 2018-2029?
  • How will political and regulatory events influence regional markets and submarkets?
  • How will the market shares of top national markets change from 2018 and which geographical region will lead the market in 2029?
  • Who are the leading companies and what are their revenue prospects over the forecast period to 2029?
  • What are the trends for M&A activity, consolidation for existing players and the prospects for new market entrants?
  • How will that industry evolve between 2018 and 2029? Where does it head and what forces change it?

Table of Contents

1. Report Overview

  • 1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
  • 1.2 How This Report Delivers
  • 1.3 Questions Answered by This Analytical Report
  • 1.4 Who is This Report For?
  • 1.5 Methodology
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2. Introduction to Pharma Wholesale and Distribution

  • 2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
    • 2.1.1 Full-Line Wholesalers (FLWs)
    • 2.1.2 Short-Line Wholesalers (SLWs)
  • 2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
    • 2.2.1 Secondary Wholesalers
    • 2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
    • 2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
    • 2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
    • 2.2.5 Pharmacy Benefit Managers
  • 2.3 Generative Revenue and Profit
    • 2.3.1 Forward Buying to Avoid Price Increases
    • 2.3.2 Fee-for-Service: A Clear Pricing Structure
    • 2.3.2.1 Inventory Management Agreements
    • 2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
    • 2.3.4 Reimbursement and Wholesalers
    • 2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
    • 2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2019-2029

  • 3.1 The World Pharmaceutical Wholesale and Distribution Market in 2018, Restricted by Government Price Reductions and Generic Substitution
  • 3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2019-2029
  • 3.3 Branded and Generic Drugs: Revenue vs. Profit, 2019-2029
    • 3.3.1 Branded and Generic Drugs: Revenue Generation, 2018
    • 3.3.2 Branded Drugs: Revenue Forecast, 2019-2029
    • 3.3.3 Generic Drugs: Revenue Forecast, 2019-2029

4. Leading Pharma Wholesalers and Distributors In 2018: Current and Future Performance

  • 4.1 McKesson: The Oldest and Largest Healthcare Services Company in the US
    • 4.1.1 McKesson: General Information
      • 4.1.1.1 McKesson, Pharmaceutical Product Category
      • 4.1.1.2 McKesson, Management Member Names
      • 4.1.1.3 McKesson, Sales Structure
      • 4.1.2 McKesson: Historical Performance, 2008-2018
    • 4.1.3 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
    • 4.1.4 McKesson: Revenue Forecast, 2019-2029
    • 4.1.5 McKesson: Strategic Moves & Developments, 2018-2019
  • 4.2 Cardinal Health: The World's Third Largest Pharma Wholesaler
    • 4.2.1 Cardinal Health: General Information
      • 4.2.1.1 Cardinal Health, Pharmaceutical Product Category
      • 4.2.1.2 Cardinal Health, Sales Structure
      • 4.2.1.3 Cardinal Health, Management Member Names
    • 4.2.2 Cardinal Health: Historical Performance, 2008-2018
    • 4.2.3 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
    • 4.2.4 Cardinal Health: Revenue Forecast, 2019-2029
    • 4.2.5 Cardinal Health: Strategic Moves & Developments, 2018-2019
  • 4.3 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
    • 4.3.1 AmerisourceBergen: General Information
      • 4.3.1.1 AmerisourceBergen, Pharmaceutical Product Category
      • 4.3.1.2 AmerisourceBergen: Sales Structure
      • 4.3.1.3 AmerisourceBergen, Management Member Names
    • 4.3.2 AmerisourceBergen: Historical Performance, 2008-2018
    • 4.3.3 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
    • 4.3.4 AmerisourceBergen: Revenue Forecast, 2019-2029
    • 4.3.5 AmerisourceBergen: Strategic Moves & Developments, 2017-2019
  • 4.4 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
    • 4.4.1 Walgreens Boots Alliance: General Information
      • 4.4.1.1 Walgreens Boots Alliance, Pharmaceutical Product Category and Brands
      • 4.4.1.2 Walgreens Boots Alliance (WBA), Sales Structure
      • 4.4.1.3 Walgreens Boots Alliance, Management Member Names
    • 4.4.2 Walgreens Boots Alliance: Historical Performance, 2011-2018
    • 4.4.3 Acquisitions and Future Strategies of Walgreens Boots Alliance
    • 4.4.4 Walgreens Boots Alliance: Revenue Forecast, 2019-2029
    • 4.4.5 Walgreens Boots Alliance: Strategic Moves & Developments, 2018-2019
  • 4.5 MEDIPAL HOLDINGS CORPORATION: Japan's Leading Pharmaceutical Wholesaler
    • 4.5.1 MEDIPAL Holdings: General Information
      • 4.5.1.1 MEDIPAL Holdings, Pharmaceutical Product Category
      • 4.5.1.2 MEDIPAL Holdings, Sales Structure
      • 4.5.1.3 MEDIPAL Holdings, Management Member Names
    • 4.5.2 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2008-2018
    • 4.5.3 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
    • 4.5.4 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2019-2029
  • 4.6 Phoenix Group: Biggest European Wholesalers
    • 4.6.1 Phoenix Group: General Information
      • 4.6.1.1 Phoenix Group, Pharmaceutical Product Category
      • 4.6.1.2 Phoenix Group, Sales Structure
      • 4.6.1.3 Phoenix Group, Management Member Names
    • 4.6.2 The PHOENIX Group: Historical Performance, 2011-2018
    • 4.6.3 Future Strategies of the PHOENIX Group: Selective Acquisition
    • 4.6.4 The PHOENIX Group: Revenue Forecast, 2019-2029
  • 4.7 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
    • 4.7.1 SINOPHARM: General Information
      • 4.7.1.1 SINOPHARM, Pharmaceutical Product and Business Category
      • 4.7.1.2 SINOPHARM, Sales Structure
      • 4.7.1.3 SINOPHARM, Management Member Names
    • 4.7.2 SINOPHARM: Historical Performance, 2011-2018
    • 4.7.3 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
    • 4.7.4 SINOPHARM: Revenue Forecast, 2019-2029
  • 4.8 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
    • 4.8.1 Alfresa Holdings: General Information
      • 4.8.1.1 Alfresa Holdings, Pharmaceutical Product and Business Category
      • 4.8.1.2 Alfresa Holdings, Sales Structure
      • 4.8.1.3 Alfresa Holdings, Management Member Names
    • 4.8.2 Alfresa Holdings: Historical Performance, 2011-2018
    • 4.8.3 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
    • 4.8.4 Alfresa Holdings: Revenue Forecast, 2019-2029
  • 4.9 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
    • 4.9.1 SUZUKEN CO., LTD: General Information
      • 4.9.1.1 SUZUKEN CO., LTD, Pharmaceutical Product and Business Category
      • 4.9.1.2 SUZUKEN CO., LTD, Sales Structure
      • 4.9.1.3 SUZUKEN CO., LTD, Management Member Names
    • 4.9.2 SUZUKEN CO. LTD: Historical Performance, 2011-2018
    • 4.9.3 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
    • 4.9.4 SUZUKEN CO., LTD: Revenue Forecast, 2019-2029
    • 4.9.5 SUZUKEN: Strategic Moves & Developments, 2018-2019
  • 4.10 Shanghai Pharmaceuticals Holding: China's Second Largest Wholesaler
    • 4.10.1 Shanghai Pharmaceuticals Holding: General Information
      • 4.10.1.1 Shanghai Pharmaceuticals Holding, Pharmaceutical Product and Business Category
      • 4.10.1.2 Shanghai Pharmaceuticals Holding; Sales Structure
      • 4.10.1.3 Shanghai Pharmaceuticals Holding Management Member Names
    • 4.10.2 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2018
    • 4.10.3 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
    • 4.10.4 Shanghai Pharma: Revenue Forecast, 2019-2029
  • 4.11 Morris & Dickson Co. LLC: Serving More than 175 Years
  • 4.12 Smith Drug Company: Serving More than 1400 Customers in U.S.
  • 4.13 Anda Inc.
    • 4.13.1 Segment Overview
    • 4.13.2 Anda Inc. Strategies:
  • 4.14 CuraScript Specialty Distribution
    • 4.14.1 Curascript Speciality Distribution Strategies:
  • 4.15 Mawdsley-Brooks & Co. Ltd.
    • 4.15.1 Mawdsley-Brooks & Co Company History:
    • 4.15.2 Mawdsley-Brooks & Co Company Strategies:
  • 4.16 North Carolina Mutual Wholesale Drug: 65 years of service
    • 4.16.1 Mutual Wholesale Drug Company History:
    • 4.16.2 Company Strategies
  • 4.17 Prodigy Health
  • 4.18 Fortissa Limited: 20 years of vast experience
  • 4.19 CR Pharmaceutical
    • 4.19.1 Company History
    • 4.19.2 Company Strategies
  • 4.20 Hygen Pharmaceuticals Inc.
    • 4.20.1 Hygen Pharmaceuticals Inc.; Key Strategies and achievements:
  • 4.21 Fff Enterprises Inc.
    • 4.21.1 Company Strengths:
    • 4.21.2 Fff Enterprises Inc.Strategies, Development and Achievements:
  • 4.22 Rochester Drug Cooperative
  • 4.23 Auburn Pharmaceutical Company
    • 4.23.1 Generic Product with Launch Dates
  • 4.24 Capital Wholesale Drug Company
  • 4.25 Realcan Pharmaceutical Group Co., Ltd.
  • 4.26 Profarma Distribuidora de Produtos Farmaceuticos SA
  • 4.27 Dakota Drug, Inc.
  • 4.28 Zhejiang Intl Group Co., Ltd.
  • 4.29 Ohki Health Care Holdings, Inc.
  • 4.30 Kingworld Medicines Group Ltd.

5. Qualitative Analysis of The Pharma Wholesale and Distribution Market

  • 5.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2018
    • 5.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
    • 5.1.2 Wholesalers Do More than Deliver Drugs
      • 5.1.2.1 Pre-Wholesaling: More Prevalent in Europe
      • 5.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
    • 5.1.3 Large Companies Dominate the Market
    • 5.1.4 Despite High Revenues, Profit Margins Are Low
    • 5.1.5 Government-Induced Drug Price Pressures Restrict Profits
    • 5.1.6 The Problem of Counterfeit Drugs
  • 5.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2019-2029
    • 5.2.1 The Demand for Pharmaceuticals is Increasing
    • 5.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
    • 5.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
    • 5.2.4 The Promotion of Drug Therapy in the US
    • 5.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
    • 5.2.6 Increased Adoption of the DTP Distribution Model
      • 5.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
      • 5.2.6.2 DTP in the UK Since 1991
      • 5.2.6.3 DTP in Poland: The Second European Country To Adopt the DTP Model
      • 5.2.6.4 Further Expansion of the DTP Model
    • 5.2.7 The Threat of Healthcare Budget Cuts
      • 5.2.7.1 Healthcare Budget Cuts in Germany
      • 5.2.7.2 Healthcare Budget Cuts in France
      • 5.2.7.3 Healthcare Budget Cuts in Italy
      • 5.2.7.4 Healthcare Budget Cuts in Spain
      • 5.2.7.5 Healthcare Budget Cuts in the UK
    • 5.2.8 Do Large Pharmacy Chains Pose a Threat?
      • 5.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
      • 5.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
    • 5.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
    • 5.2.10 The Threat of Industry Consolidation
  • 5.3 Social, Technological, Economic and Political Factors Influencing the Market, 2018-2029 (STEP Analysis)
    • 5.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
    • 5.3.2 Political Factor: Combating Counterfeit Medicines
      • 5.3.2.1 The US and E-Pedigree: Becoming Law in California
      • 5.3.2.2 European Pedigree Legislation
      • 5.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
      • 5.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?

6. Conclusions

  • 6.1 The Future of the Pharma Wholesale and Distribution Market
  • 6.2 The Leading National Pharma Wholesale and Distribution Markets
  • 6.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
  • 6.4 Trends in the Pharma Wholesale and Distribution Industry
    • 6.4.1 Generics Will Threaten Revenue
    • 6.4.2 Manufacturers Will Deliver More Drugs Directly
    • 6.4.3 There Will Be Greater Demand for Specialty Medicines
    • 6.4.4 Consolidation Will Drive Growth
    • 6.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top